…
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
bioMérieux is a global diagnostics company that develops, manufactures and sells in vitro diagnostic solutions for clinical microbiology, molecular diagnostics and industrial applications such as food safety. Long-term growth drivers include rising demand for infectious disease testing, antimicrobial resistance surveillance, expansion of molecular and point-of-care diagnostics, and growth in emerging markets, which may benefit recurring-revenue consumable sales and R&D-driven product upgrades. Investors may find the company attractive due to its established market position, broad product portfolio and predictable consumables-backed revenue streams.
Principal risks include regulatory and reimbursement changes, intense competition from larger diagnostics firms, demand variability after pandemic-related surges, exposure to currency and supply-chain disruptions, and execution risk from acquisitions and new product rollouts.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 525.30M | 579.30M | 437.40M | 580.50M | 774.30M |
| Minority interest | 0.60M | 7.10M | 34.80M | 11.80M | 2.90M |
| Net income | 397.35M | 432.20M | 357.60M | 452.40M | 601.10M |
| Selling general administrative | 1111.20M | 313.80M | 295.00M | 253.20M | 242.60M |
| Selling and marketing expenses | - | 783.80M | 725.50M | 701.50M | 575.70M |
| Gross profit | 2141.20M | 2215.30M | 2057.30M | 2008.60M | 1963.70M |
| Reconciled depreciation | 438.40M | 325.20M | 388.50M | 277.00M | 231.00M |
| Ebit | 560.99M | 595.30M | 569.00M | 665.60M | 802.90M |
| Ebitda | 999.23M | 897.50M | 857.80M | 942.60M | 1033.90M |
| Depreciation and amortization | 438.24M | 302.20M | 288.80M | 277.00M | 231.00M |
| Operating income | 560.99M | 588.80M | 439.00M | 587.20M | 784.30M |
| Other operating expenses | 3507.29M | 3391.10M | 3235.70M | 2925.30M | 2575.20M |
| Interest expense | 15.80M | 16.56M | 4.40M | 4.10M | 9.10M |
| Tax provision | 128.80M | 154.30M | 114.50M | 140.10M | 175.60M |
| Interest income | 13.20M | 0.50M | 1.40M | 1.20M | 1.70M |
| Net interest income | 4.30M | -9.40M | -1.70M | -5.20M | -9.80M |
| Income tax expense | 128.75M | 154.30M | 114.50M | 140.10M | 175.60M |
| Total revenue | 4068.28M | 3979.90M | 3674.70M | 3589.00M | 3376.20M |
| Total operating expenses | 1580.21M | 1626.50M | 1618.30M | 1344.90M | 1162.70M |
| Cost of revenue | 1927.08M | 1764.60M | 1617.40M | 1580.40M | 1412.50M |
| Total other income expense net | -35.69M | -9.50M | -1.60M | -6.70M | -10.00M |
| Net income from continuing ops | 396.80M | 425.10M | 322.90M | 440.40M | 598.00M |
| Net income applicable to common shares | - | - | - | 452.40M | 601.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5572.61M | 5770.00M | 5259.20M | 5186.60M | 4616.80M |
| Intangible assets | 401.35M | 492.00M | 528.60M | 625.00M | 411.50M |
| Other current assets | - | 156.40M | 215.70M | 38.80M | 43.70M |
| Total liab | 1468.15M | 1559.00M | 1507.00M | 1543.70M | 1442.20M |
| Total stockholder equity | 4100.56M | 4204.90M | 3752.20M | 3604.20M | 3123.20M |
| Other current liab | 670.95M | 686.10M | 606.00M | 122.50M | 95.90M |
| Common stock | 12.00M | 12.00M | 12.00M | 12.00M | 12.00M |
| Capital stock | 12.00M | 12.00M | 12.00M | 12.00M | 12.00M |
| Retained earnings | 397.50M | 432.20M | 357.60M | 452.40M | 601.10M |
| Other liab | - | - | - | 94.20M | 123.70M |
| Good will | 727.53M | 730.40M | 698.80M | 812.50M | 669.50M |
| Other assets | - | -0.10M | 0.10M | 0.10M | 0.10M |
| Cash | 569.59M | 449.80M | 352.40M | 552.60M | 803.50M |
| Total current liabilities | 1064.30M | 1134.90M | 1087.30M | 1131.10M | 955.90M |
| Current deferred revenue | - | - | 52.80M | 552.20M | 520.80M |
| Net debt | -108.36M | 40.90M | 166.40M | -47.20M | -341.00M |
| Short term debt | 131.35M | 141.00M | 163.40M | 187.00M | 99.70M |
| Short long term debt | 99.30M | 111.60M | 136.10M | 160.80M | 99.70M |
| Short long term debt total | 461.23M | 490.70M | 518.80M | 505.40M | 462.50M |
| Other stockholder equity | 4088.57M | 3760.70M | 3401.10M | 3139.80M | 2510.10M |
| Property plant equipment | - | - | - | 1369.90M | 1224.80M |
| Total current assets | 2539.45M | 2501.10M | 2205.20M | 2216.60M | 2207.10M |
| Net tangible assets | - | - | - | 2166.70M | 2042.10M |
| Short term investments | - | - | 14.20M | -19.80M | -27.50M |
| Net receivables | 1010.52M | 857.60M | 728.60M | 740.10M | 701.40M |
| Long term debt | 211.30M | 207.10M | 234.10M | 224.80M | 362.80M |
| Inventory | 959.34M | 1037.30M | 908.50M | 737.20M | 634.60M |
| Accounts payable | 262.00M | 272.40M | 265.10M | 269.40M | 239.50M |
| Accumulated other comprehensive income | - | - | -18.50M | - | - |
| Non currrent assets other | 10.30M | 24.80M | 114.60M | 12.80M | 12.50M |
| Non current assets total | 3033.16M | 3268.90M | 3054.00M | 2969.90M | 2409.60M |
| Capital lease obligations | 150.80M | 172.00M | 148.60M | 119.90M | 122.40M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -1.00M | -359.80M | -488.80M | -528.10M | -0.40M |
| Change to liabilities | - | - | - | 9.90M | 24.20M |
| Total cashflows from investing activities | -461.53M | -359.80M | -488.80M | -528.10M | -307.30M |
| Net borrowings | -29.60M | -74.80M | -34.80M | 14.30M | -50.10M |
| Total cash from financing activities | -155.34M | -212.60M | -122.30M | -244.20M | -127.00M |
| Change to operating activities | - | - | - | 71.90M | -21.80M |
| Net income | 397.35M | 425.10M | 322.80M | 440.50M | 598.20M |
| Change in cash | 173.28M | 108.70M | -195.30M | -258.60M | 416.00M |
| Begin period cash flow | 396.31M | 333.40M | 528.70M | 787.30M | 371.30M |
| End period cash flow | 569.59M | 442.10M | 333.40M | 528.70M | 787.30M |
| Total cash from operating activities | 788.00M | 667.30M | 445.40M | 475.10M | 811.10M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 438.24M | 325.20M | 258.90M | 277.00M | 231.00M |
| Other cashflows from investing activities | -0.10M | 0.60M | -0.00M | - | - |
| Dividends paid | 106.06M | 100.20M | 100.20M | -101.20M | -73.10M |
| Change to inventory | -10.10M | -85.10M | -192.60M | -92.10M | -62.40M |
| Change to account receivables | -28.99M | -53.70M | -13.70M | -145.60M | 23.60M |
| Sale purchase of stock | -18.19M | -37.60M | - | -157.20M | -3.80M |
| Other cashflows from financing activities | -1.50M | - | 12.70M | -0.10M | 18.20M |
| Change to netincome | - | - | - | -98.40M | -1.40M |
| Capital expenditures | 335.17M | 345.80M | 338.30M | 286.70M | 290.10M |
| Change in working capital | -71.27M | -51.00M | -206.70M | -155.90M | -36.40M |
| Stock based compensation | 26.50M | 23.40M | 19.70M | 13.00M | 12.40M |
| Other non cash items | 23.69M | -55.40M | 50.70M | -3.60M | 24.00M |
| Free cash flow | 452.83M | 321.50M | 107.10M | 188.40M | 521.00M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMXMF bioMérieux S.A |
- -% |
97.34 | 29.26 | 19.27 | 3.43 | 2.58 | 2.59 | 12.40 |
| TMO Thermo Fisher Scientific Inc |
-17.51 2.54% |
671.24 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.25 0.11% |
220.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.77 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.92 3.87% |
22.85 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
376 Chemin De l?Orme, Marcy-l'Étoile, France, 69280
33 4 78 87 20 00
14562
| Name | Title | Year Born |
|---|---|---|
| Mr. Alexandre Merieux | Chairman & CEO | 1974 |
| Mr. Pierre Boulud | Chief Operating Officer of Clinical Operations | 1971 |
| Mr. Frederic Beseme | Head of CSR | 1956 |
| Mr. Guillaume Bouhours | Exec. VP of Purchasing and Information Systems & CFO | 1976 |
| Sylvain Morgeau | Investor Relations | NA |
| Ms. Valerie Leylde | Exec. VP of HR, Communications & CSR | NA |
| Mr. François Lacoste | Exec. VP of R&D | NA |
| Mr. Mark Miller | Exec. VP of Medical Affairs | NA |
| Mr. Pierre Charbonnier | Exec. VP of Quality, Manufacturing & Supply Chain | NA |
| Mr. Yasha Mitrotti | Exec. VP of Industrial Microbiology | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.